Kinase Inhibitor [EPC]

385475 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS PALBOCICLIB SORAFENIB ACALABRUTINIB AXITINIB LAROTRECTINIB VANDETANIB ABEMACICLIB AFATINIB BRIGATINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 44446
1 FATIGUE 34435
2 DIARRHOEA 31117
3 NAUSEA 22388
4 OFF LABEL USE 21857
5 RASH 14604
6 MALIGNANT NEOPLASM PROGRESSION 14081
7 ASTHENIA 13840
8 DECREASED APPETITE 13542
9 DYSPNOEA 13192
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 234 0.8478
1 CYTOGENETIC ANALYSIS ABNORMAL 401 0.5050
2 NEOPLASM PROGRESSION 12134 0.4684
3 ACQUIRED GENE MUTATION 414 0.4539
4 CHRONIC MYELOID LEUKAEMIA RECURRENT 157 0.3896
5 TRANSPLANT DYSFUNCTION 496 0.3727
6 CARBOHYDRATE ANTIGEN 15-3 INCREASED 165 0.3518
7 HAEMATOCRIT ABNORMAL 310 0.3305
8 TUMOUR MARKER INCREASED 1028 0.3142
9 NON-SMALL CELL LUNG CANCER 914 0.3130
See all enriched reactions for Kinase Inhibitor [EPC]